Our data also confirmed that those patients with the HER2+ or triple-negative subtype had a significantly greater risk of developing LM than those with the HR+/HER2- subtype in YBC, which is consistent with previous research on the metastatic patterns of different BC subtypes (22–24). The gene discussed is ERBB2; the disease is breast cancer.